NEW YORK, Nov. 20, 2014 (GLOBE NEWSWIRE) — AXIM Biotechnologies (OTC:AXIM) brings to market global innovative solutions that set the “green standard” in the industrial hemp industry. The Company selected the coastal city of Almere, The Netherlands, for its future manufacturing facility headquarters. AXIM Biotechnologies has executed an option agreement for a land purchase of a 5,328 m2 industrial parcel. In addition, the Company holds an agreement for design and feasibility services with a commercial real estate developer GS Bouw based in Amsterdam, The Netherlands.
A photo accompanying this release is available at http://www.globenewswire.com/newsroom/prs/?pkgid=29240
AXIM Biotechnologies envisions an office building featuring: a clean laboratory zone, storage areas, office and technical rooms as well as manufacturing facility furnishings. Project design and feasibility has already started and the construction is planned to be completed by 2017.
“Here at AXIM, we are delighted to initiate the acquisition of a land parcel at the city of Almere at The Netherlands,” states Dr. George E. Anastassov, MD, DDS, MBA, and Chief Executive Officer of AXIM Biotechnologies. “We are extremely thankful to the government of the province of Flevoland for their trust in AXIM Biotechnologies, Inc. The factory that we will build there is compliant with the highest European and International standards and will produce unique pharmaceutical and nutraceutical products from our extended proprietary portfolio.”
Research shows that the industrial hemp plant can produce more than 25,000 products. Focusing on innovations in health and the environment, the AXIM Biotechnologies Almere facility will include raw material and finished product manufacturing in the following categories:
The state-of-the-art Almere facility will serve as AXIM’s global manufacturing hub, with both the capacity to manufacture the products and also to process hemp oil derivatives. AXIM Biotechnologies is focused upon unique proprietary delivery mechanisms for the introduction of cannabinoids (i.e. CBD, CBG, CBN) and finding solutions for conditions for which there is currently no effective treatment.
“AXIM has developed and is in the process of developing and manufacturing various end products for different indications and markets,” states Mr. Lekhram Changoer, MSc., BSc., and Chief Technology Officer of AXIM Biotechnologies. “We are excited to announce that we will now start with the preparation of the construction of the building. The manufacturing location is an important step in being the global market leader in industrial hemp development and production of different end products for customers and patients.”
Persons interested in future updates about the facility can monitor updates at AXIMBiotechnologies.com or AXIM social media channels for more photos and information. To arrange for media interviews, contact Andrew Hard, Public Relations Spokesperson, at Andrew.Hard@AXIMBiotechnologies.com or call 858-380-5478.
About AXIM Biotechnologies:
AXIM Biotechnologies (OTC:AXIM) is an innovative biotechnology company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products where we prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, visit the Company website at www.AXIMBiotech.com.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.
AXIM Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). The company does grow, sell, and distribute hemp-based products.
The photo is also available at Newscom, www.newscom.com, and via AP PhotoExpress.
CONTACT: North American Address:
18 East 50th Street, 5 Floor
New York, NY 10022
+1 844 294 6246
Boelewerf 32, Unit 3
2987 VD Ridderkerk, The Netherlands
+31 10 8209 227
Article source: http://money.cnn.com/news/newsfeeds/articles/globenewswire/10109363.htm